Veracyte (VCYT) just posted Q1 2026 results with revenue of US$139.1 million and basic EPS of US$0.36, while trailing 12 month figures show revenue of US$541.7 million and basic EPS of US$1.11, alongside a 166.3% year over year earnings increase and net margins at 16.2% versus 7.1% a year earlier. Over recent quarters the company has seen revenue move from US$114.5 million in Q1 2025 to US$139.1 million in Q1 2026, with basic EPS ranging from US$0.09 to US$0.52 in interim periods. This sets up a picture of expanding profitability for investors to weigh.

See our full analysis for Veracyte.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the key bull, bear and consensus narratives investors have been using to frame Veracyte's story.

TTM revenue hits US$541.7 million

• On a trailing 12 month basis, Veracyte booked US$541.7 million in revenue and US$88.0 million in net income, with basic EPS at US$1.11 over that period.
• Consensus narrative points to expanding cancer diagnostics and new launches as growth drivers, and the trailing 9.7% revenue growth rate and 16.2% net margin show the current business supporting that view, even though analysts also highlight that these growth rates are below the cited broader US market benchmarks.

Margins at 16.2% with rich 37.3x P/E

• Net margin sits at 16.2% on trailing 12 month earnings of US$88.0 million, while the stock trades on a trailing P/E of about 37.3x compared with 17.6x for the US Biotechs industry and 31.3x for peers.
• Bears argue that high valuation multiples leave little room for disappointment, and the current 37.3x P/E together with forecast earnings growth of about 8.6% a year versus the higher 16.1% US market benchmark supports that caution, even as the company remains profitable and has a history of positive earnings over the past five years.
  • The gap between Veracyte’s P/E and the industry average suggests the market is paying a premium relative to many other US biotech stocks despite the slower forecast growth.
  • At the same time, profitability over several years and current positive margins show that the bearish concern is centered more on pricing versus growth, not on a lack of earnings.

On the latest results and valuation, skeptics say the bar is set high for future growth to justify a premium multiple, especially with forecast growth running below the US market, and they dig deeper into that case in the 🐻 Veracyte Bear Case.

DCF fair value above US$54 vs US$41.19 price

• The shares trade at US$41.19 against a DCF fair value of about US$54.38, a gap of roughly 24.3%, while analysts’ consolidated price target is cited at US$46.80.
• Bullish investors point to this discount to both DCF fair value and the analyst target as support for upside, and the trailing 166.3% earnings growth and 16.2% net margin back the idea that the current business performance lines up with a stronger long term story, even if the P/E is already higher than industry and peer averages.
  • The combination of positive net income of US$88.0 million and a share price below the DCF fair value gives bulls a concrete valuation reference tied to cash flow expectations.
  • However, the same data set also shows the premium multiple and below market forecast growth, which is where bullish and bearish narratives clearly diverge on how much that valuation gap really matters.

For investors who want to see how optimistic analysts build a case around this valuation gap and earnings profile, there is a full bullish narrative available in 🐂 Veracyte Bull Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Veracyte on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing both the bullish and bearish narratives, how does the story look to you right now? Review the potential upside factors for yourself and see what stands out in the 3 key rewards.

See What Else Is Out There

Veracyte combines a rich 37.3x P/E with forecast earnings growth below the broader US market, which raises questions about how much investors are paying for that outlook.

If that mix of a premium price tag and more modest expected growth gives you pause, compare it with companies screened for stronger value signals using the 45 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.